The expression levels of PDE4D have been reported to be notably higher in the synovium and TNF-α-treated FLSs of RA patients6, suggesting that PDE4D may be an effective target for RA treatment, particularly in the context of hyperproliferative FLSs. The gene discussed is PDE4D; the disease is rheumatoid arthritis.